14.25
5.63%
-0.85
After Hours:
14.56
0.31
+2.18%
MediWound Ltd stock is currently priced at $14.25, with a 24-hour trading volume of 175.16K.
It has seen a -5.63% decreased in the last 24 hours and a -0.84% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $15.29 pivot point. If it approaches the $14.11 support level, significant changes may occur.
MediWound Ltd Stock (MDWD) Financials Data
MediWound Ltd (MDWD) Revenue 2023
MDWD reported a revenue (TTM) of $24.97 million for the quarter ending September 30, 2023, a +22.59% rise year-over-year.
MediWound Ltd (MDWD) Net Income 2023
MDWD net income (TTM) was -$12.43 million for the quarter ending September 30, 2023, a +23.75% increase year-over-year.
MediWound Ltd (MDWD) Cash Flow 2023
MDWD recorded a free cash flow (TTM) of -$10.28 million for the quarter ending September 30, 2023, a +38.14% increase year-over-year.
MediWound Ltd (MDWD) Earnings per Share 2023
MDWD earnings per share (TTM) was -$1.76 for the quarter ending September 30, 2023, a +52.92% growth year-over-year.
MediWound Ltd Stock (MDWD) Latest News
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
Zacks Investment Research
What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
Zacks Investment Research
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
Zacks Investment Research
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
MediWound to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
About MediWound Ltd
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Cap:
|
Volume (24h):